SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : BIOTECH & TECHNOLOGY INVESTING *UNDERVALUED*{T/A F/A & V}
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: BRAVEHEART who wrote (40)1/30/1999 5:32:00 PM
From: QuietWon  Read Replies (1) of 423
 
Finally, a thoughtful, insightful, and top it off well articulated post.

I don;t know VION, so thank you. And a great move !

I took a look at VION's website and could not find the type of info I found for IMCL and ONXX. Not having that info, I can't at the moment make that comparison.

However, I can say, IMCL having 100% of patients with more than 50% tumour reduction, and 88% having 100% regression that must be excellent! No side effects reported - the whole idea behind this non-chemo generation of drugs is to localize, thus having reduced chances of side effects.

In summary, take the assump that side effects pretty much the same in IMCL, ONXX, VION , then IMCL is pretty darn impressive. Certainly, IMCL beats ONXX hands down.

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News